Document is current
Any future updates will be listed below
-
Authors
Lautenbach, Anne https://orcid.org/0000-0002-7763-1527
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Mijuskovic, Ana
Jones, Lucy https://orcid.org/0009-0004-7805-1112
Schirmann, Felix https://orcid.org/0000-0002-0057-902X
- License Information
-
More Information
Article History
Received: 10 April 2025
Revised: 30 October 2025
Accepted: 17 November 2025
First Online: 17 December 2025
Competing interests
: The research was fully funded by Oviva AG. AM, FS, and LJ are employed at Oviva AG. MB received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. AL received honoraria as a consultant and speaker from AstraZeneca, Lilly, Novo Nordisk, Boehringer Ingelheim, and Oviva.
: The study protocol has been approved by the ethics committee of the Berlin Medical Association (vote number: Eth-57/23) and was registered in the German Clinical Trials Register (Registration number: DRKS00033045). All participants provided written informed consent before participation, and all procedures were performed in accordance with the relevant guidelines and regulations.
